This HTML5 document contains 70 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00392/identifier/bindingdb/
n17http://linked.opendata.cz/resource/AHFS/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00392/identifier/pubchem-compound/
n22http://linked.opendata.cz/resource/mesh/concept/
n20http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00392/identifier/kegg-drug/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00392/identifier/pubchem-substance/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00392/identifier/drugbank/
n24http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00392/identifier/chemspider/
owlhttp://www.w3.org/2002/07/owl#
n21http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00392/identifier/chebi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00392/identifier/wikipedia/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00392/identifier/pharmgkb/
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00392
rdf:type
n3:Drug
n3:description
Ethopropazine (also known as profenamine hydrochloride) is a medication derived from phenothiazine. It is primarily used as an antidyskinetic to treat parkinsonism. It is sold under the trade names Parsidol in the United States and Parsidan in Canada.
n3:group
approved
n3:halfLife
1 to 2 hours
n3:indication
For use in the treatment of Parkinson's disease and also used to control severe reactions to certain medicines such as reserpine.
n3:manufacturer
n20:271B4138-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00392 n24:DB00392
dcterms:title
Ethopropazine
adms:identifier
n6:8958 n7:313639 n10:46507375 n11:PA449531 n12:3290 n15:D01118 n16:3174 n18:DB00392 n25:Ethopropazine
n3:mechanismOfAction
Ethopropazine's antiparkinson action can be attributed to its anticholinergic properties. Ethopropazine partially blocks central (striatal) cholinergic receptors, thereby helping to balance cholinergic and dopaminergic activity in the basal ganglia; salivation may be decreased, and smooth muscle may be relaxed. Drug-induced extrapyramidal symptoms and those due to parkinsonism may be relieved, but tardive dyskinesia is not alleviated and may be aggravated by anticholinergic effects. Ethopropazine's local anesthetic effect is due to its antagonism of the NMDA glutamate receptor. Glutamate is recognized as an important transmitter in nociceptive pathways, and the N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor, in particular, has been implicated in the mediation of neuropathic pain. Excessive release of glutamate at NMDA receptors on dorsal horn neurons of the spinal cord results in hyperactivation and hypersensitivity of these receptors (perceived as hyperalgesia), thought to be an integral feature of neuropathic pain.
n3:synonym
2-Diethylamino-1-propyl-N-dibenzoparathiazine Ethopropazine 10-[2-(Diethylamino)propyl]phenothiazine Profenamine N,N-Diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine 10-(2-Diethylaminopropyl)phenothiazine Profenamina 10-[2-(Diethylamino)-1-propyl]phenothiazine N,N-Diethyl-alpha-methyl-10H-phenothiazine-10-ethanamine 10-[2-(Diethylamino)-2-methylethyl]phenothiazine Profenaminum
n3:toxicity
Symptoms of overdose include severe clumsiness or unsteadiness, severe drowsiness, severe dryness of mouth, nose, or throat, fast heartbeat, shortness of breath or troubled breathing, and warmth, dryness, and flushing of skin.
n13:hasAHFSCode
n17:12-08-04
n3:proteinBinding
93%
n3:salt
n3:synthesisReference
Berg, S.S. and Ashley, J.N.; U.S. Patent 2,607,773; August 19,1952; assigned to Societe des Usines Chimiques Rhone-Poulenc, France.
n21:hasConcept
n22:M0225290
n3:IUPAC-Name
n4:271B413E-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4144-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4143-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4140-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4141-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4142-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4153-363D-11E5-9242-09173F13E4C5 n4:271B413C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4155-363D-11E5-9242-09173F13E4C5 n4:271B413D-363D-11E5-9242-09173F13E4C5 n4:271B413A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B413B-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:N04AA05
n3:H-Bond-Acceptor-Count
n4:271B414A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B414B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4145-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4146-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4148-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4147-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4149-363D-11E5-9242-09173F13E4C5
n3:absorption
Well-absorbed from the gastrointestinal tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
1094-08-2
n3:category
n3:containedIn
n19:271B4139-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B414F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4151-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4152-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4154-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B414E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B414D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4150-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B413F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B414C-363D-11E5-9242-09173F13E4C5